China’s Hutchison MediPharma Freezes Development Of Cancer Drug, Signs Development Deal With Janssen

BEIJING - Shanghai-headquartered Hutchison MediPharma has frozen development of a cancer drug after Phase II clinical trials conducted in China produced inconclusive data on the efficacy of the medicine, according to company executives

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip